Conventional treatments for eye diseases such as Glaucoma and Dry Eye Disease are insufficient- they require frequent dosing (multiple times a day for some meds), can be painful to dose and patient compliance can be as low as 50%. The goal of 20/20 OptimEyes Technologies is to use our proprietary micelle platform technology to better control the release of drugs. This will allow for prolonged drug penetration into the eye, meaning patients can use a comfortable drop only once or twice per week.

20/20 OptimEyes Technologies

Org chart

Teams

Offices